Cargando…

Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective

Kittens immunized with purified native FeLV-gp70 or -gp85 envelope proteins developed ELISA, but not virus neutralizing, antibodies in their serum to both whole FeLV and FeLV-gp70. Kittens vaccinated with envelope proteins and infected with feline sarcoma virus (FeSV) developed smaller tumors than n...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, N.C., Johnson, L., Birch, D., Theilen, G.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 1986
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125533/
https://www.ncbi.nlm.nih.gov/pubmed/3008409
http://dx.doi.org/10.1016/0165-2427(86)90093-0
_version_ 1783515965955244032
author Pedersen, N.C.
Johnson, L.
Birch, D.
Theilen, G.H.
author_facet Pedersen, N.C.
Johnson, L.
Birch, D.
Theilen, G.H.
author_sort Pedersen, N.C.
collection PubMed
description Kittens immunized with purified native FeLV-gp70 or -gp85 envelope proteins developed ELISA, but not virus neutralizing, antibodies in their serum to both whole FeLV and FeLV-gp70. Kittens vaccinated with envelope proteins and infected with feline sarcoma virus (FeSV) developed smaller tumors than nonvaccinates, but a greater incidence of persistent retroviremia. Similarly, FeLV-gp70 and -gp85 vaccinated kittens were more apt to become persistently retroviremic following virulent FeLV challenge exposure than nonvaccinates. Kittens vaccinated with inactivated whole FeLV developed smaller tumors after FeSV inoculation and had a lower incidence of persistent retroviremia than nonvaccinates. The protective effect of inactivated whole FeLV vaccine against persistent retroviremia was also seen with FeLV challenge-exposed cats. Protection afforded by inactivated whole FeLV vaccine was not associated with virus neutralizing antibodies, although ELISA antibodies to both whole FeLV and FeLV-gp70 were induced by vaccination.
format Online
Article
Text
id pubmed-7125533
institution National Center for Biotechnology Information
language English
publishDate 1986
publisher Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71255332020-04-08 Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective Pedersen, N.C. Johnson, L. Birch, D. Theilen, G.H. Vet Immunol Immunopathol Article Kittens immunized with purified native FeLV-gp70 or -gp85 envelope proteins developed ELISA, but not virus neutralizing, antibodies in their serum to both whole FeLV and FeLV-gp70. Kittens vaccinated with envelope proteins and infected with feline sarcoma virus (FeSV) developed smaller tumors than nonvaccinates, but a greater incidence of persistent retroviremia. Similarly, FeLV-gp70 and -gp85 vaccinated kittens were more apt to become persistently retroviremic following virulent FeLV challenge exposure than nonvaccinates. Kittens vaccinated with inactivated whole FeLV developed smaller tumors after FeSV inoculation and had a lower incidence of persistent retroviremia than nonvaccinates. The protective effect of inactivated whole FeLV vaccine against persistent retroviremia was also seen with FeLV challenge-exposed cats. Protection afforded by inactivated whole FeLV vaccine was not associated with virus neutralizing antibodies, although ELISA antibodies to both whole FeLV and FeLV-gp70 were induced by vaccination. Published by Elsevier B.V. 1986-02 2002-11-12 /pmc/articles/PMC7125533/ /pubmed/3008409 http://dx.doi.org/10.1016/0165-2427(86)90093-0 Text en Copyright © 1986 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Pedersen, N.C.
Johnson, L.
Birch, D.
Theilen, G.H.
Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective
title Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective
title_full Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective
title_fullStr Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective
title_full_unstemmed Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective
title_short Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective
title_sort possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125533/
https://www.ncbi.nlm.nih.gov/pubmed/3008409
http://dx.doi.org/10.1016/0165-2427(86)90093-0
work_keys_str_mv AT pedersennc possibleimmunoenhancementofpersistentviremiabyfelineleukemiavirusenvelopeglycoproteinvaccinesinchallengeexposuresituationswherewholeinactivatedvirusvaccineswereprotective
AT johnsonl possibleimmunoenhancementofpersistentviremiabyfelineleukemiavirusenvelopeglycoproteinvaccinesinchallengeexposuresituationswherewholeinactivatedvirusvaccineswereprotective
AT birchd possibleimmunoenhancementofpersistentviremiabyfelineleukemiavirusenvelopeglycoproteinvaccinesinchallengeexposuresituationswherewholeinactivatedvirusvaccineswereprotective
AT theilengh possibleimmunoenhancementofpersistentviremiabyfelineleukemiavirusenvelopeglycoproteinvaccinesinchallengeexposuresituationswherewholeinactivatedvirusvaccineswereprotective